Equity Details
Price & Market Data
Price: $0.322
Daily Change: -$0.0191 / 5.93%
Daily Range: $0.322 - $0.342
Market Cap: $14,772,850
Daily Volume: 2,138,508
Performance Metrics
1 Week: -15.31%
1 Month: 27.18%
3 Months: 65.93%
6 Months: 16.13%
1 Year: -37.80%
YTD: 52.99%
About Theriva Biologics, Inc. (TOVX)
Get immediate market data for Theriva Biologics, Inc. (TOVX). Price: 0.322, daily change: -$0.0191 / 5.93%. Market cap: 14,772,850. All performance metrics at your fingertips.
Company Details
Employees: 16
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.